InvestorsHub Logo
Followers 13
Posts 3218
Boards Moderated 0
Alias Born 04/26/2007

Re: None

Saturday, 10/30/2021 5:37:43 PM

Saturday, October 30, 2021 5:37:43 PM

Post# of 40501
TBA in coming weeks: Report complete REVEAL 1 data (ITT, mITT, per protocol)
Report on pre-treatment biomarker with QIAGEN
Present GBM INO-5401 24-month overall survival and immunology data
Fully enroll Phase 1 Ebola study with INO-4201 as a booster to Ervebo®

INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees (Boost-EBOV)
https://clinicaltrials.gov/ct2/show/NCT04906629?term=Inovio&draw=4&rank=49

Drum roll for …4802 P1/2 start and external fundings…. Kick-started by:

10/29 Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates

The studies described in this manuscript were funded by a grant from the Coalition for Epidemic Preparedness Innovations (CEPI).
https://www.biorxiv.org/content/10.1101/2021.10.27.466163v1
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INO News